Lisata Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

0
20
Lisata Therapeutics, Inc. announced that it has reached agreement with the European Medicines Agency on a Pediatric Investigation Plan for Lisata’s lead investigational product, certepetide in pancreatic cancer.
[Lisata Therapeutics, Inc.]
Press Release